Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Endocr J. 2010;57(9):787-92. doi: 10.1507/endocrj.k10e-178. Epub 2010 Aug 6.
Familial hypocalciuric hypercalcemia (FHH) is a benign disorder with heterozygous inactivating mutations in the calcium-sensing receptor (CASR) gene. The present study describes the identification and functional analysis of a novel CASR gene mutation leading to FHH. The proband is a 33-yr-old woman (Ca 11.0 mg/dL, intact-PTH 68 pg/mL, FECa 0.17 %). Leukocyte DNA was isolated in four family members and a novel heterozygous mutation (D190G, GAT>GGT) in exon 4 of CASR gene was identified by direct sequence analysis. The mutant CASR expression vector was constructed by mutagenesis procedure and its response to Ca(2+) was characterized by transient transfection into human embryonic kidney (HEK) 293 cells and treatment with increasing extracellular Ca(2+) concentrations. HEK cells didn't activate intracellular signaling (MAPK activation) in response to increases of extracellular Ca(2+) concentrations when the mutant receptor was expressed normally at the cell surface. The novel heterozygous mutation (D190G) identified in the present study showed that the reduction of activity of CASR to extracellular Ca(2+) caused FHH in patients and our study demonstrated the importance of Asp-190 participated in response to Ca(2+) in CASR.
家族性低钙血症性高钙血症(FHH)是一种良性疾病,其特征为钙敏感受体(CASR)基因的杂合失活突变。本研究描述了导致 FHH 的新型 CASR 基因突变的鉴定和功能分析。先证者是一名 33 岁女性(Ca 11.0mg/dL,完整-PTH 68pg/mL,FECa 0.17%)。从 4 名家族成员中分离白细胞 DNA,并通过直接序列分析鉴定 CASR 基因第 4 外显子中的新型杂合突变(D190G,GAT>GGT)。通过突变程序构建突变型 CASR 表达载体,并通过瞬时转染入人胚肾(HEK)293 细胞和用递增的细胞外 Ca(2+)浓度处理来表征其对 Ca(2+)的反应。当突变受体正常表达在细胞表面时,HEK 细胞不会对外界 Ca(2+)浓度的增加产生细胞内信号(MAPK 激活)。本研究中鉴定的新型杂合突变(D190G)表明,CASR 对细胞外 Ca(2+)的活性降低导致患者出现 FHH,我们的研究证明了 Asp-190 参与 CASR 对 Ca(2+)的反应的重要性。